Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Some patients report feeling unusually tired or experiencing reduced energy levels, particularly in the initial weeks of treatment
It is often studied in models focused on melanocyte response, appetite-related signaling, and other mechanisms linked to melanocortin receptor activation
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins
US25OZM00781 August 2025 SOURCE Novo Nordisk
